Lamotrigine Farmax

Lamotrigine, the active ingredient in Lamotrigine Farmax, is an anticonvulsant presented as a tablet for oral use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures, and as a maintenance therapy for bipolar disorder, helping to stabilize mood in affected patients.

GNH USA supplies Lamotrigine Farmax as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and through reliable and efficient timely global distribution for healthcare providers.

Lamotrigine is used in the management of seizure disorders and mood stabilization, acting on neuronal excitability.

- Partial seizures: reduces frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes in primary generalized epilepsy. - Bipolar disorder (maintenance therapy): stabilizes mood and decreases risk of depressive or manic episodes.

Lamotrigine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Nausea: feeling of stomach upset. - Rash: mild skin irritation or erythema. - Blurred vision: temporary visual disturbances. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction with blistering and mucosal involvement. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Aseptic meningitis: inflammation of the meninges without infection. - Blood dyscrasias: including agranulocytosis or aplastic anemia. - Hepatotoxicity: liver injury indicated by elevated enzymes. - Suicidal thoughts: emergence or worsening of depressive or suicidal ideation.

Before prescribing lamotrigine, clinicians should consider several safety and handling precautions. - Initiate therapy at low dose: start with a low dose and titrate gradually to reduce rash risk. - Monitor skin reactions: discontinue immediately if a widespread rash or signs of Stevens‑Johnson syndrome appear. - Assess hepatic function: evaluate liver function before starting and during therapy, especially in patients with hepatic impairment. - Review concomitant medications: avoid drugs that significantly alter lamotrigine metabolism, such as valproate, which can increase plasma levels. - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Lamotrigine’s plasma concentrations can be altered by several co‑administered medicines, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Valproic acid: markedly increases lamotrigine levels; co‑administration may require dose reduction. - Carbamazepine: induces metabolism, reducing lamotrigine concentrations and efficacy. - Phenobarbital: strong enzyme inducer that lowers lamotrigine exposure.

Moderate Interactions (Monitor Closely): - Oral contraceptives: estrogen‑containing pills can decrease lamotrigine levels, possibly reducing seizure control. - Sertraline: may increase risk of rash when combined with lamotrigine. - Phenytoin: moderate enzyme induction may lower lamotrigine levels.